Ambar Qavi

1.5k total citations · 1 hit paper
9 papers, 670 citations indexed

About

Ambar Qavi is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Ambar Qavi has authored 9 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 3 papers in Virology and 2 papers in Emergency Medicine. Recurrent topics in Ambar Qavi's work include HIV/AIDS Research and Interventions (5 papers), HIV/AIDS drug development and treatment (5 papers) and HIV Research and Treatment (3 papers). Ambar Qavi is often cited by papers focused on HIV/AIDS Research and Interventions (5 papers), HIV/AIDS drug development and treatment (5 papers) and HIV Research and Treatment (3 papers). Ambar Qavi collaborates with scholars based in United Kingdom, South Africa and United States. Ambar Qavi's co-authors include Andrew Hill, Simiso Sokhela, Kaitlyn McCann, François Venter, Bryony Simmons, Celicia Serenata, Godspower Akpomiemie, Nomathemba Chandiwana, Michelle Moorhouse and Natasha Arulappan and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and AIDS.

In The Last Decade

Ambar Qavi

9 papers receiving 665 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

2019 442 citations François Venter, Michelle Moorhouse et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ambar Qavi United Kingdom	7	503	368	245	104	46	9	670
Barbara Menzaghi Italy	16	316 0.6×	270 0.7×	180 0.7×	115 1.1×	74 1.6×	46	534
Simiso Sokhela South Africa	12	606 1.2×	484 1.3×	326 1.3×	132 1.3×	59 1.3×	31	791
Sally Bebawy United States	12	457 0.9×	319 0.9×	240 1.0×	177 1.7×	27 0.6×	21	646
Nomathemba Chandiwana South Africa	9	474 0.9×	372 1.0×	248 1.0×	105 1.0×	39 0.8×	26	628
Francesca Rocchi Italy	12	144 0.3×	133 0.4×	164 0.7×	116 1.1×	84 1.8×	26	752
Sally Skinner United States	13	343 0.7×	369 1.0×	117 0.5×	317 3.0×	130 2.8×	15	797
Celicia Serenata South Africa	12	654 1.3×	376 1.0×	352 1.4×	184 1.8×	43 0.9×	18	831
Masebole Masenya South Africa	4	366 0.7×	303 0.8×	195 0.8×	78 0.8×	32 0.7×	4	481
Nkuli Mashabane South Africa	5	356 0.7×	302 0.8×	200 0.8×	74 0.7×	33 0.7×	7	478
Patricia Echeverría Spain	13	227 0.5×	263 0.7×	147 0.6×	62 0.6×	17 0.4×	40	481

Countries citing papers authored by Ambar Qavi

Since Specialization

Citations

This map shows the geographic impact of Ambar Qavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ambar Qavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ambar Qavi more than expected).

Fields of papers citing papers by Ambar Qavi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ambar Qavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ambar Qavi. The network helps show where Ambar Qavi may publish in the future.

Co-authorship network of co-authors of Ambar Qavi

This figure shows the co-authorship network connecting the top 25 collaborators of Ambar Qavi. A scholar is included among the top collaborators of Ambar Qavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ambar Qavi. Ambar Qavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Mitchell, Chris, et al.. (2023). Radiological analysis and outcomes of isolated greater tuberosity fracture-dislocations. Annals of The Royal College of Surgeons of England. 106(3). 270–276. 1 indexed citations

2.

Akpomiemie, Godspower, Nomathemba Chandiwana, Simiso Sokhela, et al.. (2022). Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clinical Infectious Diseases. 76(8). 1492–1495. 36 indexed citations

3.

Pepperrell, Toby, François Venter, Kaitlyn McCann, et al.. (2021). Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. Clinical Infectious Diseases. 73(4). e1008–e1010. 17 indexed citations

4.

McCann, Kaitlyn, Andrew Hill, Ambar Qavi, et al.. (2021). Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 35(10). 1657–1665. 52 indexed citations

5.

Alturkistani, Abrar, et al.. (2020). Patient Portal Functionalities and Patient Outcomes Among Patients With Diabetes: Systematic Review. Journal of Medical Internet Research. 22(9). e18976–e18976. 24 indexed citations

6.

Yakoot, Mostafa, et al.. (2020). Efficacy and Safety of Sofosbuvir/Daclatasvir in the Treatment of COVID-19: A Randomized, Controlled Study. SSRN Electronic Journal. 2 indexed citations

7.

Sadeghı, Anahita, Ali Asgari, Alireza Norouzi, et al.. (2020). Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. Journal of Antimicrobial Chemotherapy. 75(11). 3379–3385. 84 indexed citations

8.

Venter, François, Michelle Moorhouse, Simiso Sokhela, et al.. (2019). Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine. 381(9). 803–815. 442 indexed citations breakdown →

9.

Venter, François, Michelle Moorhouse, Simiso Sokhela, et al.. (2019). Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. The Lancet HIV. 6(7). e428–e437. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact